Infergen Promotion Produced By Third Party Lands Kadmon In Hot Water With DDMAC
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Division of Drug Marketing, Advertising and Communications cites Kadmon for failing to include risk information and overstating efficacy in a "STATgram" promoting its hepatitis C treatment interferon alfacon-1.